Related references
Note: Only part of the references are listed.VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Kan V. Lu et al.
CANCER CELL (2012)
HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis
Farbod Shojaei et al.
CANCER LETTERS (2012)
Exploiting pleiotropic activities of semaphorins as multi-target therapies for cancer
Lidia Moserle et al.
EMBO MOLECULAR MEDICINE (2012)
Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform
Andrea Casazza et al.
EMBO MOLECULAR MEDICINE (2012)
Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice
Federica Maione et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors
Alicia S. Chung et al.
JOURNAL OF PATHOLOGY (2012)
Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models
Mallika Singh et al.
JOURNAL OF PATHOLOGY (2012)
Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors
Barbara Sennino et al.
CANCER DISCOVERY (2012)
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
Peter Friedl et al.
CELL (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Cancer cells metabolically fertilize the tumor microenvironment with hydrogen peroxide, driving the Warburg effect Implications for PET imaging of human tumors
Ubaldo E. Martinez-Outschoorn et al.
CELL CYCLE (2011)
Is the Postprogression Survival Time Really Not Shortened in the Bevacizumab-Containing Arms of Phase III Clinical Trials?
Piotr Potemski
JOURNAL OF CLINICAL ONCOLOGY (2011)
Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials
David Miles et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
John M. L. Ebos et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?
Katrien De Bock et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Inflammation-mediated promotion of invasion and metastasis
Graziella Solinas et al.
CANCER AND METASTASIS REVIEWS (2010)
Understanding the lethal drivers of tumor-stroma co-evolution Emerging role(s) for hypoxia, oxidative stress and autophagy/mitophagy in the tumor micro-environment
Michael P. Lisanti et al.
CANCER BIOLOGY & THERAPY (2010)
Hypoxia and Hypoxia-Inducible Factors: Master Regulators of Metastasis
Xin Lu et al.
CLINICAL CANCER RESEARCH (2010)
Cancer Dissemination-Lessons from Leukocytes
Chris D. Madsen et al.
DEVELOPMENTAL CELL (2010)
Mechanisms of resistance to antiangiogenesis therapy
Faisal Azam et al.
EUROPEAN JOURNAL OF CANCER (2010)
TARGETED THERAPIES Sunitinib versus interferon-alpha in metastatic RCC
Jason E. Faris et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Patterns of Disease Progression in Metastatic Renal Cell Carcinoma Patients Treated With Antivascular Agents and Interferon Impact of Therapy on Recurrence Patterns and Outcome Measures
Elizabeth R. Plimack et al.
CANCER (2009)
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M. L. Ebos et al.
CANCER CELL (2009)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
MET receptor tyrosine kinase as a therapeutic anticancer target
Christine M. Stellrecht et al.
CANCER LETTERS (2009)
Endothelial Cells Form a Phalanx to Block Tumor Metastasis
Victoria L. Bautch
CELL (2009)
Heterozygous Deficiency of PHD2 Restores Tumor Oxygenation and Inhibits Metastasis via Endothelial Normalization
Massimiliano Mazzone et al.
CELL (2009)
Hypoxia, angiogenesis and cancer therapy To breathe or not to breathe?
Paolo Michieli
CELL CYCLE (2009)
Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies
Annamaria Rapisarda et al.
DRUG RESISTANCE UPDATES (2009)
Mechanisms of collective cell migration at a glance
Olga Ilina et al.
JOURNAL OF CELL SCIENCE (2009)
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
R. M. Zuniga et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Anticancer strategies involving the vasculature
Victoria L. Heath et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Antiangiogenic therapies for high-grade glioma
Andrew D. Norden et al.
NATURE REVIEWS NEUROLOGY (2009)
Hypoxia Generates a More Invasive Phenotype of Tumour Cells: An In Vivo Experimental Setup Based on the Chorioallantoic Membrane
Resit Demir et al.
PATHOLOGY & ONCOLOGY RESEARCH (2009)
The clinical implications of the genetics of renal cell carcinoma
Inger Rosner et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2009)
Microenvironmental regulation of metastasis
Johanna A. Joyce et al.
NATURE REVIEWS CANCER (2009)
Graded hypoxia modulates the invasive potential of HT1080 fibrosarcoma and MDA MB231 carcinoma cells
Patrick Subarsky et al.
CLINICAL & EXPERIMENTAL METASTASIS (2008)
Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Angiogenesis as a strategic target for ovarian cancer therapy
Whitney A. Spannuth et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2008)
Pericytes: gatekeepers in tumour cell metastasis?
Holger Gerhardt et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2008)
Modes of resistance to anti-angiogenic therapy
Gabriele Bergers et al.
NATURE REVIEWS CANCER (2008)
VEGF-targeted therapy: mechanisms of anti-tumour activity
Lee M. Ellis et al.
NATURE REVIEWS CANCER (2008)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Sunitinib versus interferon-alfa (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors
R. J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase III Randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors
Robert J. Motzer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients
Tracy T. Batchelor et al.
CANCER CELL (2007)
Molecular basis for sunitinib efficacy and future clinical development
Sandrine Faivre et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway
Takao Ide et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Pericytes limit tumor cell metastasis
XJ Xian et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche
RN Kaplan et al.
NATURE (2005)
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors
O Casanovas et al.
CANCER CELL (2005)
A multitargeted, metronomic, and maximum-tolerated dose chemo-switch regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer
K Pietras et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
The hypoxic response of tumors is dependent on their microenvironment
B Blouw et al.
CANCER CELL (2003)
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
G Bergers et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Tumour-cell invasion and migration: Diversity and escape mechanisms
P Friedl et al.
NATURE REVIEWS CANCER (2003)
Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene
S Pennacchietti et al.
CANCER CELL (2003)
Genetic modulation of hypoxia induced gene expression and angiogenesis: Relevance to brain tumors
DJ Brat et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2003)
Integrin-mediated adhesion regulates cell polarity and membrane protrusion through the Rho family of GTPases
EA Cox et al.
MOLECULAR BIOLOGY OF THE CELL (2001)
Share Paper
